Literature DB >> 18021749

Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2.

A G Golub1, O Ya Yakovenko, A O Prykhod'ko, S S Lukashov, V G Bdzhola, S M Yarmoluk.   

Abstract

Protein kinase CK2 (Casein Kinase 2) is an extremely pleiotropic Ser/Thr kinase with high constitutive activity. The observation of CK2 deregulations in various pathological processes suggests that CK2 inhibitors may have a therapeutic value, particularly as anti-neoplastic and antiviral drugs. Here, we present the 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as a novel potent class of CK2 inhibitors. We identified this class of inhibitors by high-throughput docking of a compound collection in the ATP-binding site of human CK2. The most active compounds are 2-(4,5,6,7-tetraiodo-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanoic acid and 2-(4,5,6,7-tetraiodo-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)acetic acid with IC(50) values of 0.15 microM and 0.3 microM, respectively. These inhibitors are ATP-competitive and they only minimally inhibit the activities of protein kinases DYRK1a, MSK1, GSK3 and CDK5. Binding modes for the most active inhibitors are proposed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18021749     DOI: 10.1016/j.bbapap.2007.10.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Expanding the chemical diversity of CK2 inhibitors.

Authors:  Renaud Prudent; Virginie Moucadel; Miriam López-Ramos; Samia Aci; Beatrice Laudet; Liliane Mouawad; Caroline Barette; Jacques Einhorn; Cathy Einhorn; Jean-Noel Denis; Gilles Bisson; Frédéric Schmidt; Sylvaine Roy; Laurence Lafanechere; Jean-Claude Florent; Claude Cochet
Journal:  Mol Cell Biochem       Date:  2008-06-18       Impact factor: 3.396

2.  Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2.

Authors:  Andriy G Golub; Volodymyr G Bdzhola; Yaroslav V Kyshenia; Vladislav M Sapelkin; Andriy O Prykhod'ko; Olexander P Kukharenko; Olga V Ostrynska; Sergiy M Yarmoluk
Journal:  Mol Cell Biochem       Date:  2011-07-07       Impact factor: 3.396

3.  Dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-4-ones as a new class of CK2 inhibitors.

Authors:  Mykola V Protopopov; Olga V Ostrynska; Sergiy A Starosyla; Maria A Vodolazhenko; Svetlana M Sirko; Nikolay Yu Gorobets; Volodymyr Bdzhola; Sergey M Desenko; Sergiy M Yarmoluk
Journal:  Mol Divers       Date:  2018-05-29       Impact factor: 2.943

4.  Treatment of cultured human astrocytes and vascular endothelial cells with protein kinase CK2 inhibitors induces early changes in cell shape and cytoskeleton.

Authors:  A A Kramerov; A G Golub; V G Bdzhola; S M Yarmoluk; K Ahmed; M Bretner; A V Ljubimov
Journal:  Mol Cell Biochem       Date:  2010-12-02       Impact factor: 3.396

5.  An experimental and theoretical approach to the molecular structure of 2-(4-[3-(2,5-dimethylphenyl)-3-methylcyclobutyl]thiazol-2-yl)isoindoline-1,3-dione.

Authors:  Namik Ozdemir; Muharrem Dinçer; Alaaddin Cukurovali
Journal:  J Mol Model       Date:  2009-07-12       Impact factor: 1.810

6.  Biochemical characterization of CK2alpha and alpha' paralogues and their derived holoenzymes: evidence for the existence of a heterotrimeric CK2alpha'-holoenzyme forming trimeric complexes.

Authors:  Birgitte B Olsen; Tine Rasmussen; Karsten Niefind; Olaf-Georg Issinger
Journal:  Mol Cell Biochem       Date:  2008-06-24       Impact factor: 3.396

7.  Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell recruitment to retinal neovascularization sites.

Authors:  A A Kramerov; M Saghizadeh; S Caballero; L C Shaw; S Li Calzi; M Bretner; M Montenarh; L A Pinna; M B Grant; A V Ljubimov
Journal:  Mol Cell Biochem       Date:  2008-07-09       Impact factor: 3.396

Review 8.  Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

Authors:  Breland Smith; Federico Medda; Vijay Gokhale; Travis Dunckley; Christopher Hulme
Journal:  ACS Chem Neurosci       Date:  2012-08-28       Impact factor: 4.418

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.